APA (7th ed.) Citation

KF, B., RA, C., GG, V., MF, P., S, N., A, P., . . . E, R. (2025). Biomarker Analysis from the Compass Claudication Study - Rivaroxaban for Intermittent Claudication. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 31, 10760296251372934. https://doi.org/10.1177/10760296251372934

Chicago Style (17th ed.) Citation

KF, Britto, et al. "Biomarker Analysis from the Compass Claudication Study - Rivaroxaban for Intermittent Claudication." Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 31 (2025): 10760296251372934. https://doi.org/10.1177/10760296251372934.

MLA (9th ed.) Citation

KF, Britto, et al. "Biomarker Analysis from the Compass Claudication Study - Rivaroxaban for Intermittent Claudication." Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, vol. 31, 2025, p. 10760296251372934, https://doi.org/10.1177/10760296251372934.